ARTICLE | Clinical News

Rindopepimut: Additional Phase II data

November 24, 2014 8:00 AM UTC

Data from 72 Avastin bevacizumab-naive patients in Group 1 of the double-blind, U.S. Phase II ReACT trial showed that 500 µg rindopepimut plus GM-CSF and Avastin led to a 6-month PFS rate, the primary endpoint, of 27% vs. 11% for Avastin plus keyhole limpet hemocyanin (KLH) (p=0.048). Additionally, rindopepimut plus GM-CSF and Avastin significantly improved median OS (12 vs. 8.8 months, p=0.0208) and improved ORR (24% vs. 17%) vs. Avastin plus KLH. In the rindopepimut arm, 74% of patients had stable disease or better for >2 months vs. 57% of patients in the Avastin plus KLH arm. ...